Coffee and amyotrophic lateral sclerosis: A possible preventive role

Ettore Beghi, Elisabetta Pupillo, Paolo Messina, Giorgia Giussani, Adriano Chiò, Stefano Zoccolella, Cristina Moglia, Massimo Corbo, Giancarlo Logroscino, Ammar Al-Chalabi, Orla Hardiman, Albert Ludolph, Douglas Mitchell, Pierre Marie Preux, Robert Swingler, Bryan J. Traynor, Elena Alvisi, Cristina Cereda, Mauro Ceroni, Antonietta CitterioMonica Bandettini di Poggio, Claudia Caponnetto, Massimiliano Bissolati, Paolo Buzzi, Irene Colombo, Fabio Formaglio, Christian Lunettam, Eleonora Maestri, Andrea Millul, Alessandro Prelle, Alessandra Protti, Nilo Riva, Domenico Santoro, Rosa Capozzo, Alberto Cat Berro, Stefania Cammarosano, Sara Giacone, Antonio Ilardi, Maria Sofia Cotelli, Massimiliano Filosto, Anna Micheli, Alessandro Padovani, Luisa De Lodovici, Carlo Ferrarese, Lucio Tremolizzo, Vincenza Fetoni, Elena Palazzini, Maria Cristina Guaita, Patrizia Perrone, Patrizia Secchi, Lorenzo Lorusso, Vincenzo Sidoti, Michele Perini, Fiorella Tavernelli, Andrea Rigamonti, Eugenio Vitelli

Research output: Contribution to journalArticle

Abstract

The relation between coffee intake and risk of amyotrophic lateral sclerosis (ALS) was investigated in 377 newly diagnosed ALS patients from 4 Italian population-based registries in the European ALS Consortium (EURALS Group) (2007-2010). For each patient, 2 age-and sex-matched hospital controls were selected, one from a neurology department and one from a nonneurologic department. Two additional healthy control groups were identified from local general practitioners' (GPs') lists (n = 99) and residents of the same area as a cancer cohort (n = 7,057). Coffee intake was defined in terms of status (ever consuming coffee daily for ≥6 months vs. never), duration, and history (never, former, or current). Ever coffee drinkers comprised 74.7% of ALS patients, 80.4% of neurologic controls, 85.6% of nonneurologic controls (P = 0.0004), 88.9% of GP controls (P = 0.0038), and 86.0% of cancer cohort controls (P <0.0001). Current coffee drinkers comprised 60.2% of ALS patients, 70.2% of neurologic controls (P = 0.0294), 76.4% of nonneurologic controls (P <0.0001), and 82.3% of GP controls (P = 0.0002); duration of intake was ≥30 years for 62.3%, 67.7%, 74.7%, and 72.6%. ALS patients had lower lifetime coffee exposure: Odds ratios were 0.7 (95% confidence interval (CI): 0.5, 1.1), 0.6 (95% CI: 0.4, 0.8), and 0.4 (95% CI: 0.2, 0.9) in comparison with neurologic, nonneurologic, and GP controls, respectively. In current (vs. never) coffee drinkers, odds ratios were 0.7 (95% CI: 0.5, 1.0), 0.5 (95% CI: 0.3, 0.7), and 0.4 (95% CI: 0.2, 0.8), respectively. These findings provide epidemiologic evidence of an inverse correlation between coffee intake and ALS risk.

Original languageEnglish
Pages (from-to)1002-1008
Number of pages7
JournalAmerican Journal of Epidemiology
Volume174
Issue number9
DOIs
Publication statusPublished - Nov 1 2011

Keywords

  • amyotrophic lateral sclerosis
  • coffee
  • motor neuron disease

ASJC Scopus subject areas

  • Epidemiology

Fingerprint Dive into the research topics of 'Coffee and amyotrophic lateral sclerosis: A possible preventive role'. Together they form a unique fingerprint.

  • Cite this

    Beghi, E., Pupillo, E., Messina, P., Giussani, G., Chiò, A., Zoccolella, S., Moglia, C., Corbo, M., Logroscino, G., Al-Chalabi, A., Hardiman, O., Ludolph, A., Mitchell, D., Preux, P. M., Swingler, R., Traynor, B. J., Alvisi, E., Cereda, C., Ceroni, M., ... Vitelli, E. (2011). Coffee and amyotrophic lateral sclerosis: A possible preventive role. American Journal of Epidemiology, 174(9), 1002-1008. https://doi.org/10.1093/aje/kwr229